A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Subjects, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Trial Profile

A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-Response of TMC114/RTV in 3-Class-Experienced HIV-1 Infected Subjects, Followed by an Open-Label Period on the Recommended Dose of TMC114/RTV.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Darunavir (Primary) ; Enfuvirtide; HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; Ritonavir
  • Indications HIV infections; HIV-1 infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms POWER-1
  • Most Recent Events

    • 17 Dec 2009 Patient numbers amended from 318 to 334 as reported by ClinicalTrials.gov.
    • 01 Nov 2009 Pooled 96-week results from the POWER-1, -2, AND -3 trials were published in Antiviral Therapy.
    • 25 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top